Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918146 | 1.00 | SMN1; SMN2 (0.64) | SMN1; SMN2RAB9AMEN1KMT2AGAA | |
| SCHEMBL4231048 | 0.99 | SMN1; SMN2 (0.62) | SMN1; SMN2RAB9AMEN1KMT2AGAA | |
| SCHEMBL2001911 | 0.95 | MEN1 (0.63) | SMN1; SMN2RAB9AMEN1KMT2AGAA | |
| SCHEMBL4234495 | 0.89 | RAB9A (0.66) | SMN1; SMN2RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL917183 | 0.86 | HDAC1 (0.65) | SMN1; SMN2RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL13486978 | 0.85 | POLB (0.67) | SMN1; SMN2RAB9AMEN1KMT2AHSD17B10 | |
| SCHEMBL8083585 | 0.84 | POLB (0.69) | SMN1; SMN2RAB9AMEN1KMT2AHSD17B10 | |
| SCHEMBL916697 | 0.83 | ALDH1A1 (0.52) | MEN1KMT2AKDM4EPOLBPKM | |
| SCHEMBL1573660 | 0.83 | ACHE (0.57) | POLB | |
| SCHEMBL8095237 | 0.83 | ACHE (0.57) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003878-A1 | NOVEL DERIVATIVES OF PHTHALIMIDE AS HISTONE DEACETYLASE INHIBITORS | UNIVERSIDAD DE GRANADA (ES) | 2011-01-06 | — | — | US | disclosed |
| US-20090215814-A1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-08-27 | — | — | US | disclosed |
| EP-2045239-A1 | NOVEL DERIVATIVES OF PHTHALIMIDE AS HISTONE DEACETYLASE INHIBITORS | Universidad De Granada (ES) | 2009-04-08 | — | — | EP | disclosed |
| US-20070078137-A1 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2007-04-05 | — | — | US | disclosed |
| US-7148352-B2 | Method of inhibiting neurotrophin-receptor binding | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-12-12 | — | — | US | disclosed |
| US-20030186901-A1 | Method of inhibiting neurotrophin-receptor binding | MINE SAFETY APPLIANCES COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-6468990-B1 | ADMINISTERING COMPOUNDS HAVING ELECTRONEGATIVE GROUPS WHICH INTERACT WITH CERTAIN LYSINE RESIDUES IN NERVE GROWTH FACTOR AND/OR HYDROPHOBIC MOIETY WHICH INTERACTS WITH HYDROPHOBIC REGION FORMED BY CERTAIN ISOLEUCINE AND PHENYLALANINE RESIDUES | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215814-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | SMN1; SMN2 707/4885RAB9A 3720/4885MEN1 3489/4885 |
| US-20110003878-A1 | NOVEL DERIVATIVES OF PHTHALIMIDE AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC11 | SMN1; SMN2 2910/4885RAB9A 3178/4885MEN1 2731/4885 |
| US-20070078137-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | SMN1; SMN2 707/4885RAB9A 3720/4885MEN1 3489/4885 |
| US-20030186901-A1 | Method of inhibiting neurotrophin-receptor binding | NGF, NTRK2, BDNF | SMN1; SMN2 708/4885RAB9A 4136/4885MEN1 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.